Citations 1
Immunotherapy‐Resistant Neuropathic Pain and Fatigue Predict Quality‐of‐Life in Contactin‐Associated Protein‐Like 2 Antibody Disease
Ceronie, Bryan , Strippel, Christine , Uy, Christopher , Paneva, Sofija , Makuch, Mateusz , Soleimani, Babak , Turaga, Sanchit, Ramanathan, Sudarshini , Michael, Sophia , Varley, James , Easton, Ava , Bennett, David , Irani, Anushka , Irani, Sarosh R. , Ramanathan, Sudarshini , Themistocleous, Andreas , Bennett, David L , Irani, Anushka , Irani, Sarosh R , Paneva, Sofija , Binks, Sophie , Dawes, John M. , Handel, Adam E.
Annals of Neurology | January 18, 2025 | Volume: 97 | Issue: 3 | Pages: 521-528
The long‐term clinical outcomes and associated prognostic factors in contactin‐associated protein‐like 2 (CASPR2)‐antibody diseases are unknown. A total of 75 participants with CASPR2 antibodies were longitudinally assessed for disability, quality‐of‐life, and chronic pain. Although most symptoms improved within 6 months of treatment, neuropathic pain and fatigue were the most immunotherapy refractory, and persisted for up to 6 years. Furthermore, these two factors—but not CASPR2 antibody levels or subclasses—independently predicted worse disability and quality‐of‐life at 24 months. Quality‐of‐life varied widely for any given modified Rankin Scale score, indicating a divergence between patient and clinician assessed outcomes. Further work should study the relative importance of these measures, and the immunopathogenesis underlying intractable symptoms. ANN NEUROL 2025;97:521–528